Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 3/20 | 0.51 |
| ▸ | CNR2 | P34972 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2927912 | 0.88 | L3MBTL1 (1.00) | L3MBTL1TDP1PTPN1LMNACES2 | |
| SCHEMBL17583713 | 0.82 | L3MBTL1 (0.80) | L3MBTL1TDP1MEN1KMT2APTPN1 | |
| SCHEMBL16807278 | 0.82 | L3MBTL1 (0.80) | L3MBTL1TDP1MEN1KMT2APTPN1 | |
| SCHEMBL17583575 | 0.82 | L3MBTL1 (0.80) | L3MBTL1TDP1PTPN1LMNACES2 | |
| Biphenyl SCHEMBL28656314 | 0.82 | L3MBTL1 (0.87) | L3MBTL1TDP1PTPN1LMNACES2 | |
| SCHEMBL2842478 | 0.82 | MEN1 (0.59) | L3MBTL1TDP1MEN1KMT2AS1PR3 | |
| SCHEMBL16807287 | 0.81 | L3MBTL1 (0.77) | L3MBTL1TDP1PTPN1LMNACES2 | |
| SCHEMBL2928039 | 0.81 | L3MBTL1 (0.77) | L3MBTL1TDP1MEN1KMT2APTPN1 | |
| SCHEMBL6201027 | 0.81 | MEN1 (0.51) | L3MBTL1TDP1MEN1KMT2AS1PR3 | |
| SCHEMBL6202239 | 0.81 | LMNA (0.74) | L3MBTL1TDP1MEN1KMT2AS1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656947-B2 | Process for creating carbon-carbon bonds using carbonyl compounds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S) (FR) | 2017-05-23 | — | — | US | disclosed |
| US-9656947-B2 | Process for creating carbon-carbon bonds using carbonyl compounds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S) (FR) | 2017-05-23 | — | — | US | disclosed |
| EP-2858966-B1 | PROCESS FOR CREATING CARBON-CARBON BONDS USING CARBONYL COMPOUNDS | CENTRE NAT RECH SCIENT (FR) | 2016-08-10 | — | — | EP | disclosed |
| US-20150166464-A1 | PROCESS FOR CREATING CARBON-CARBON BONDS USING CARBONYL COMPOUNDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N. R.S.) (FR) | 2015-06-18 | — | — | US | disclosed |
| US-20150166464-A1 | PROCESS FOR CREATING CARBON-CARBON BONDS USING CARBONYL COMPOUNDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N. R.S.) (FR) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166464-A1 | PROCESS FOR CREATING CARBON-CARBON BONDS USING CARBONYL COMPOUNDS | CBR3, CBR1, CYP4F3 | L3MBTL1 4386/4885TDP1 4876/4885MEN1 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.